P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line

New Microbiologica

Volumn 27, Issue 2 SUPPL. 1, 2004, Pages 119-126

  Maffeo, A ^a   Bellomi, F ^a   Solimeo, I ^a   Bambacioni, F ^b   Scagnolari, C ^a   De Pisa, F ^a   Dupuis, M L ^c   Cianfriglia, M ^c   Antonelli, G ^a   Turriziani, O ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HIV; P glycoprotein; Protease inhibitors

Indexed keywords

ANTIVIRUS AGENT; GLYCOPROTEIN P; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; VALSPODAR; VINBLASTINE;

ANTIVIRAL ACTIVITY; CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG UPTAKE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CELLS, CULTURED; GENE EXPRESSION REGULATION; HIV; HIV PROTEASE INHIBITORS; HUMANS; P-GLYCOPROTEIN; RNA, MESSENGER; SAQUINAVIR; T-LYMPHOCYTES;

EID: 19944426763     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. ANKEL, H., TURRIZIANI, O. AND ANTONELLI, G. (1991). Prostaglandin A inhibits replication of human immunodeficiency virus during acute infection. Journal of General Virology, 72, 2797-2800.
2. ANTONELLI, G., TURRIZIANI, O., CIANFRIGLIA, M., RIVA, E., DONG, G., FATTOROSSI, A. AND DIANZANI F. (1992). Resistance of HIV-1 to AZT might also involve expression of multidrug resistant P-glycoprotein. AIDS Research and Human Retroviruses, 8, 1838-1844.
3. ANTONELLI, G., SIMEONI, E., TURRIZIANI, O., TESORO, R., REDAELLI, A., ROFFI, L., ANTONELLI, L., PISTELLO, M. AND DIANZANI F. (1999). Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-α therapy. Journal of Interferon and Cytokine Research, 19, 243-251.
4. BARG, S., RENSTROEM, E., BERGGREN, P.O., BERTORELLO, A., BOKVIST, K., BRAUN, M., ELIASSON, L., HOLMES, W.E., KHOELER, M., RORSMAN, P. AND THÉVENOD, F. (1999). The stimulatory action of tolbutamide on Ca2+ -dependent exocytosis in pancreatic cells is mediated by a 65 -kDa mdr-like P-glycoprotein. Proceedings of the National Academy of Sciences of the USA 96, 5539-5544.
5. BECK, W.T., MUELLER, T.J. AND TANZER, L.R. (1979). Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemia lymphoblast. Cancer Research, 39, 2070-2076.
6. BOMMHARDT, U., CEROTTINI, J.C, AND MACDONALD, H.R. (1994). Heterogeneity in P-glycoprotein (multidrug resistance) activity among murine peripheral T cells: correlation with surface phenotype and effector function. European Journal of Immunology, 24, 2974-2981.
7. BOSCH, I. AND CROOP, J. (1996). P-glycoprotein multidrug resistance and cancer. Biochimica et Biophysica Acta, 1288 (2), F37-F54.
8. CHIN, J.E., SOFFIR, R., NOONAN, K.E., CHOIK, K. AND RONINSON, I.B. (1989). Structure and expression of the human MDR (P-glycoprotein) gene family. Molecular and Cellular Biology, 9, 3808-3820.
9. CIANFRIGLIA, M., CENCIARELLI, C., TOMBESI, M., BARCA, S., MARIANI, M., MORRONE, S., SANTONI, A., SAMOGGIA, P., ALESSIO, M. AND MALAVASI, W. (1990). Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multi-drug-resistant variants of CEM cells. International Journal of Cancer, 45, 95-103.
10. CIANFRIGLIA, M., WILLINGHAM, M.C., TOMBESI, M., SCAGLIOTTI, G.V., FRASCA, G. AND CHERSI, A. (1994). Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug-resistant cells. International Journal of Cancer, 56, 153-160.
11. CORDON-CARDO, C., O'BRIEN, J.P., BOCCIA, J., CASALS, D., BERTINO, J.R. AND MELAMED, M.R. (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human and tumor tissues. Journal of Histochemistry and Cytochemistry 38, 1277-1287.
12. DEY. S., RAMACHANDRA, M., PASTAN, I., GOTTESMAN, M.M. AND AMBUDKAR, S.C. (1997). Evidence for two non-identical drug-interaction sites in the human P-glycoprotein. Proceedings of the National Academy of Sciences of the USA, 94, 10594-10599.
13. EL-OSTA, A., KANTHARIDIS, P. AND ZALCBERG, J. (1999). Absolute quantitation of MDR1 transcripts using heterologous DNA standards-validation of the competitive RT-PCR (CRT-PCR) approach. Bio Techniques, 26, 1114-1124.
14. FORD, J., MEADEN, E.R., HOGGARD, P.G., DALTON, M., NEWTON, P., WILLIAMS, I., KHOO, S.H. AND BACK, D.J. (2003). Effect of protease inhibitor-containing regimes on lymphocyte multidrug resistance transporter expression. Journal of Antimicrobial Chemotherap.y 52, 354-358.
15. GOLLAPUDI, S. AND GUPTA, S. (1990). Human immunodeficiency virus 1-induced expression of P-glycoprotein. Biochemical Biophysical Research Communications, 171, 1002-1007.
16. HAMADA, H. AND TSURUO, T. (1986). Functional role for the 170 to 180-Kda glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proceedings of the National Academy of Sciences of the USA, 83, 7785-7789.
17. Hu, J.M. AND HSIUNG, G.D. (1989). Evaluation of new antiviral agents: in vitro perspectives. Antiviral Research, 11, 217-232.
18. JONES, K., HOGGARD, P.G., SALES, S.D., KHOO, S., DAVEY, R. AND BACK, D.J. (2001a). Differences in the intracellular uptake of HIV protease inhibitors in vitro and the effect of active transport. AIDS, 15, 675-681.
19. JONES, K., BRAY, P.G., KHOO, S.H., DAVEY, R.A., MEADEN, E.R., WARD, S.A. AND BACK, D.J. (2001b). P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS, 15, 1353-1358.
20. KARTNER, N., RIORDAN, J.R. AND LING, V. (1983). Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science, 221, 1285-1288.
21. KAWAI, K., KUSANO, I., IDO, M., SAKURAI, M., SHIRAISHI, T. AND VATANI, R. (1994). Identification of a P-glycoprotein-related protein (mini-P- glycoprotein) which is overexpressed in multidrug resistant cells. Biochemical and Biophysical Research Communications, 198, 804-810.
22. KEMPF, D.J., MARSH, K.C., KUMAR, G., RODRIGUES, A.D., DENISSEN, J.F., MCDONALD, E., KUKULKA, M.J., HSU, A., GRANNEMAN, G.R., BAROLDI, P.A., SUN, E., PIZZUTI, D., PLATTNER, J.J., NORBECK, D.W. AND LEONARD, J.M. (1997). Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrobial Agents and Chemotherapy, 41, 654-660.
23. KIM, R.B., FROMM, M.F., WANDEL, C., LEAKE, B., WOOD, A.J.J. AND RODEN, D.M. (1998). The drug transporter P glycoprotein limits oral absorption and brain entry of HIV-1 proteinase inhibitors. Journal of Clinical Investigations, 101, 289-294.
24. LEE, C.G.L, RAMACHANDRA, M., JEANG, K-T., MARTIN, M.A., PASTAN, I. AND GOTTESMAN, M.M., (2000). Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB Journal, 14, 516-522.
25. LUCIA, M.B., CAUDA, R., LANDAY, A.L., MALORNI, W., DONELLI, G. AND ORTONA, L. (1995). Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. AIDS Research and Human Retroviruses 11, 893-901.
26. LUDESCHER, C., PALL, G., IRSCHICK, E.U., AND GASTL, G. (1998). Differential activity of P-glycoprotein in normal blood lymphocytes subsets. British Journal of Haematology, 101, 722-727.
27. MA, J.E., GRANT, G., STAELENS, B., HOWARD, D.L. AND MELERA, P.W. (1999). In vitro translation of a 2.3-kb splicing variant of the hamster pgp1 gene whose presence in transfectants is associated with decreased drug resistance. Cancer Chemotherapy and Pharmacology, 43, 19-28.
28. MEADEN, E.R., HOGGARD, P.G., MAHER, B., KHOO, S.H. AND BACK, D.J. (2001). Expression of p-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected individuals. AIDS Research and Human Retroviruses, 17, 1329-1332.
29. PERLOFF, M.D., VON MOLTKE L.L., FAHEY, J.M., DAILY, J.P. AND GREEBLATT, D.J. (2000). Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS, 14, 1287-1289.
30. PUDDU, P., GHERARDI, G., FAIS, S., LUCANI, F., ROMAGNOLI, G., CIANFRUGLIA, M. AND GESSANI, S. (1999). Interferon-γ upregulates P-glycoprotein expression in human peripheral blood monocyte-derived macrophages. Laboratory Investigation, 79, 1299-1309.
31. ROMAGNOLI, G., POLONI, F., FLEGO, M., MORETTI, F., DI MODUGNO, F., CHERSI, A., FALASCA, G., SIGNORETTI, C., CASTAGNA, M. AND CIANFRUGLIA, M. (1999). Epitope mapping of the monoclonal antibody MM12.10 to external MDR1 P-glycoprotein domain by synthetic peptide scanning and phage display technologies. Biological Chemistry, 380, 553-559.
32. SRINIVAS, R.V., MIDDLEMAS, D., FLYNN, P. AND FRIDLAND, A. (1998). Human immunodeficiency virus protease-inhibitors serve as substrate for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrobial Agents & Chemotherapy, 42, 3157-3162.
33. THÉVENOD, F., HILDEBRANDT, J.P., STRIESSING, J., DE JONGE, H.R. AND SCHULZ, I. (1996). Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by an approximately 80-kDa MDR1a gene product. Journal of Biological Chemistry, 271, 3300-3305.
34. TRAMBAS, C., WANG, Z., CIANFRIGLIA, M. & WOODS, G. (2001). Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. British Journal of Haematology, 114, 177-184.
35. TURRIZIANI, O., DI MARCO P., ANTONELLI G. AND DIANZANI F. (2000) May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors? Antimicrobial Agents & Chemotherapy, 44, 473-747.
36. UEDA, K, CORWELL, MM, GOTTESMAN, MM, PASTAN, I, RONINSON, IB, LING, V, AND RIORDAN, JR. (1986) The mdr1 gene, responsible for multidrug resistance, codes for P-glycoprotein. Biochemical & Biophysical Research Communications, 141, 956-962.
37. VAN DER SANDT, ICJ, Vos, CMP, NABULSI, L, BLOMROOSEMALEN, MCM, VOORWINDEN, HH, DE BOER, AG, AND BREIMER, DD. (2001) Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS, 15, 483-491.
38. VAN HEESWIJK, RP, VELDKAMP, AI, HOETELMANS, RM, MULDER, JW, SCHREIJ, G, HSU, A, LANGE, JM, BEIJNEN, JH, AND MEENHORST, PL. (1999) The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals. AIDS, 13 (14):F95-99.
39. WASHINGTON, CB, DURAN, GE, MAN, MC, SIKIC, BI, AND BLASCHKE, TF. (1998) Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Journal of Acquired Immune Deficiency Syndromes and Human Retrivirology, 19, 203-209.